Skip to main content
Monthly Archives

April 2020

La urticaria crónica (CUR) contribuye a la comprensión y el conocimiento de la enfermedad en la región.

Impact of treatment with bilastine for PD-1/PD-L1 inhibitors induced rash

By Articles about Bilastine

Hirata T.

Ann Oncol. 2019 Feb;30 Suppl 1:i13. doi: 10.1093/annonc/mdz026.005. Epub 2020 Jan 8

Several tumors are treated with PD-1/PD-L1 inhibitors, such as nivolumab, pembrolizumab, atezolizumab. However, these are known to induce rash in some cases. Rash treatment included antihistamines and corticosteroids. Bilastine is a non-sedating second generation H1-antihistamine, but its effectiveness in rash caused by PD-1/PD-L1 inhibitors is unknown. The aim of this study was to assess the efficacy of bilastine in these cases.

This study included 84 patients with PD-1/PD-L1 rash of a group of 224 patients from a Japanese medical center between September 2014 and October 2018. They were classified into 4 groups according to the systemic antihistamine and topical corticosteroid therapy: (1) bilastine and corticosteroid group (n = 18), (2) another antihistamine and corticosteroid group (n = 22), (3) bilastine only group (n = 20) and (4) another antihistamine group (n = 24).

The group in bilastine and corticosteroid showed a significantly shorter median duration of treatment than group 2. Bilastine group had a significantly shorter period of systemic medications than the another antihistamine group. Adverse events reported included somnolence (3 %), headache (3 %) and dizziness (3 %) and no serious adverse events were reported.

In conclusion, bilastine treatment reduced the need and duration of topical corticosteroid use in PD-1/PD-L1 inhibitors induced rash with a good safety profile.

This document is only available for registered healthcare professionals


Bilastine: a lifetime companion for the treatment of allergies

By Eprint

Martin K Church, Marysia Tiongco-Recto, Erminia Ridolo & Zoltán Novàk.

(2019) Current Medical Research and Opinion, DOI: 10.1080/03007995.2019.1681134

Bilastine is a potent and highly selective H1-antihistamine for the treatment of urticaria and allergic rhinoconjunctivitis.

This is a review article that gathers information available up to 25 February 2019 on the use of the H1-antihistamine bilastine in the treatment of allergic disorders in different age groups, from children to adults.

Teenagers and adults bilastine dose is usually 20 mg daily and children up to 12 years old is 10 mg of bilastine once daily. Bilastine has demonstrated efficacy at improving allergic rhinitis symptoms, such as nasal and ocular symptoms and at improving wheals and itching in urticaria. It has a rapid onset of action and a long duration of action.

Bilastine does not interact with the CYP450 system, making it a H1-antihistamine free from drug-drug interactions. Patients with renal or hepatic impairment or elderly ones don’t need dosage adjustment. Bilastine is well tolerated, even at above standard doses and doesn’t exhibit anticholinergic or cardiotoxic effects. It has minimal sedative properties due to its inexistence central nervous system penetration. Patients on bilastine show an overall improvement of health-related quality of life.

In conclusion, bilastine is a suitable option of H1-antihistamins for the treatment of allergic rhinoconjunctivitis or urticaria in all patients.

This document is only available for registered healthcare professionals.

Close Menu

La información que está a punto de visualizar está dirigida únicamente a los profesionales sanitarios aptos para prescribir o dispensar medicamentos. La correcta utilización de su contenido requiere de formación como profesional sanitario.

Debe hacer clic en Aceptar para confirmar que es usted profesional de la salud y continuar con la navegación.